1. Home
  2. TG vs BDTX Comparison

TG vs BDTX Comparison

Compare TG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

HOLD

Current Price

$7.71

Market Cap

262.4M

Sector

Industrials

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

N/A

Current Price

$2.10

Market Cap

171.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TG
BDTX
Founded
1988
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
262.4M
171.9M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
TG
BDTX
Price
$7.71
$2.10
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$9.67
AVG Volume (30 Days)
143.0K
521.4K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
130.71
EPS
0.34
N/A
Revenue
$800,821,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.82
N/A
Revenue Growth
8.29
N/A
52 Week Low
$6.25
$1.60
52 Week High
$10.53
$4.94

Technical Indicators

Market Signals
Indicator
TG
BDTX
Relative Strength Index (RSI) 50.52 52.18
Support Level $7.57 $1.96
Resistance Level $8.12 $2.28
Average True Range (ATR) 0.23 0.10
MACD -0.02 -0.02
Stochastic Oscillator 46.98 26.97

Price Performance

Historical Comparison
TG
BDTX

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: